Silverback Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Silverback Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100,000	Closed	-$783K	–	66
2025 Q1	$783K	Sell	100,000 -100,000	-50%	-$837K	0.11%	54
2024 Q4	$2.1M	Buy	200,000 +100,000	+100%	+$1.21M	0.31%	60
2024 Q3	$1.31M	Buy	+100,000	New	+$1.52M	0.18%	70
2024 Q2	–	Sell	-100,000	Closed	-$1.69M	–	83
2024 Q1	$1.69M	Hold	100,000	–	–	0.23%	67
2023 Q4	$1.41M	Buy	+100,000	New	+$1.17M	0.2%	73
2023 Q2	–	Sell	-348,600	Closed	-$3.19M	–	92
2023 Q1	$3.19M	Sell	348,600 -27,200	-7%	-$224K	0.43%	65
2022 Q4	$2.69M	Buy	375,800 +75,800	+25%	+$532K	0.37%	76
2022 Q3	$1.5M	Buy	+300,000	New	+$1.65M	0.21%	77

Other funds holding AVDL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Silverback Asset Management's AVDL Position: Q4 2025 in Review

Silverback Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 110,000 shares — an estimated $1.68M sold.

Silverback Asset Management first reported a position in AVDL in Q3 2023 and held it in 4 quarters. The position peaked at $1.68M in Q3 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

Silverback Asset Management reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Silverback Asset Management sold 110,000 Avadel Pharmaceuticals shares in Q4 2025, an estimated $1.68M.
Silverback Asset Management first reported a position in Avadel Pharmaceuticals in Q3 2023 and held it in 4 quarters.
Silverback Asset Management's Avadel Pharmaceuticals position peaked at $1.68M in Q3 2025.
207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Silverback Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.